We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

OBT Licenses BioWa’s POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer

News   Apr 07, 2011

 
OBT Licenses BioWa’s POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer
 
 
 

RELATED ARTICLES

Dual Anthrax-Plague Vaccine Effective in Multiple Animal Models

News

A dual vaccine against the causative agents of anthrax and the plague is effective in three animal models.

READ MORE

Antibody Combo Suppressed HIV Levels in Early Trial

News

In an early trial, a combination of two antibodies suppressed blood levels of HIV for months after treatment in some people.

READ MORE

Urine Point-of-care Test Detects Antibiotic-resistant 'Superbugs'

News

A simple and inexpensive new test can diagnose patients with antibiotic-resistant strains of bacteria in a matter of minutes.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE